Drug Profile
Hydrocodone controlled-release - Currax Pharmaceuticals
Alternative Names: AFI-001; Hydrocodone bitartrate; Hydrocodone ER; Hydrocodone extended release; Zohydro ER; ZX 007; ZX-002Latest Information Update: 09 Mar 2022
Price :
$50
*
At a glance
- Originator Daravita
- Developer Zogenix
- Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Pain
Most Recent Events
- 07 Mar 2022 Zogenix has been acquired by UCB
- 30 Apr 2019 Currax Pharmaceuticals acquired all the assets of Pernix Therapeutics ,
- 07 Sep 2018 Pernix Therapeutics, LLC, and Pernix Ireland Pain Designated Activity Company files a notice of appeal to the United States Court of Appeals for the Federal Circuit